High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients.
Frémont, Marc, Coomans, Danny, Massart, Sebastien et al. · Anaerobe · 2013 · DOI
Quick Summary
This study examined bacteria in the gut of ME/CFS patients compared to healthy people. Researchers found that ME/CFS patients have different types and amounts of gut bacteria than healthy controls, particularly an overgrowth of certain bacteria and a decrease in others. These differences suggest that gut bacteria imbalance may be linked to ME/CFS, and testing for these specific bacteria changes might help diagnose the condition or guide new treatments like probiotics.
Why It Matters
This research provides objective evidence that gut bacteria composition is altered in ME/CFS, offering a potential biological marker for diagnosis and a target for new microbiota-based treatments. For patients experiencing gastrointestinal symptoms—a common complaint in ME/CFS—this work validates that there may be real, measurable changes in their gut bacteria that could eventually guide personalized treatment approaches.
Observed Findings
Norwegian ME/CFS patients showed increased proportions of Lactonifactor and Alistipes bacteria compared to controls.
Norwegian ME/CFS patients demonstrated decreased levels of several Firmicutes populations.
Belgian and Norwegian healthy controls had different baseline microbiota compositions, with Norwegians showing higher Firmicutes (Roseburia, Holdemania) and lower Bacteroidetes.
Belgian ME/CFS patients showed less pronounced dysbiosis than Norwegian patients, though some abnormalities overlapped between populations.
Inferred Conclusions
Intestinal dysbiosis is present in ME/CFS patients and represents a measurable biological alteration associated with the disease.
High-throughput 16S rRNA sequencing is a viable diagnostic tool for detecting dysbiosis in ME/CFS.
Microbiota-modulating treatments such as antibiotics, prebiotics, or probiotics may be therapeutic strategies worth investigating for ME/CFS.
Remaining Questions
Does dysbiosis cause ME/CFS symptoms, or is it a consequence of the disease or lifestyle factors associated with ME/CFS?
Which specific dysbiosis patterns are universal to ME/CFS across different geographic populations, and which are environmentally determined?
What This Study Does Not Prove
This study demonstrates correlation between dysbiosis and ME/CFS but cannot prove that dysbiosis causes ME/CFS or that correcting dysbiosis will improve symptoms. The cross-sectional design means we cannot determine the direction of causality, and the significant differences between Belgian and Norwegian control populations suggest that dysbiosis patterns may vary by geography, making it unclear which bacterial changes are universally relevant to ME/CFS pathogenesis.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only